Loading the session
Loading the session
Loading instrument
$5.18
−1.15%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:20 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +14.2% (SPY −1.6%). 3 months: +80.1% (SPY −0.4%). 1 year: +15.4% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ACB, SPY · as of 4 Nov 2026
8.2M shares were sold short at the 15 Oct 2026 settlement, 12.5% of the 65.7M shares outstanding; covering them would take 5.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $5.24 was 27.8% above its 50-day average ($4.10) and 47.6% above its 200-day average ($3.55). It has closed above the 200-day for 55 sessions, since 19 Aug 2026. The 50-day average crossed above the 200-day on 30 Sep 2026, 25 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
4 Nov 2026 volume of 3.2M shares was 2.5× the average of the 30 sessions before it (1.3M), as the price rose 1.6%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
The 14-session relative strength index closed at 78.6 on 4 Nov 2026, its 2nd session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.
February 5, 2025
+45.92%April 30, 2024
+46.04%September 11, 2023
+72.17%